ArticleWorld journal of microbiology & biotechnology2026
Stratified cumulative antibiograms and antimicrobial resistance trends among hospitalized patients in a Chinese tertiary hospital: a 7-year retrospective study.
Article in World journal of microbiology & biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Antimicrobial Resistance Profile ofAntibiotics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hospital-wide cumulative antibiograms guide empirical therapy but may conceal clinically relevant resistance heterogeneity across inpatient settings. We conducted a retrospective, single-center study of inpatient antimicrobial susceptibility testing (AST) data collected at a Chinese tertiary hospital from 2019 to 2025. For each patient, the first isolate of each organism in each calendar year was selected and its complete AST panel retained. The primary comparison was between adult intensive care unit (ICU) wards and all other inpatient wards. Temporal trends were assessed using the conventional Cochran-Armitage test with false discovery rate correction, and sensitivity analyses excluded hospital-based SARS-CoV-2 high-activity periods. The analysis included 45,645 index isolates from 26,297 patients. Meropenem resistance among Acinetobacter baumannii isolates was 90.7% in adult ICU wards versus 61.9% in non-ICU wards. Corresponding ICU versus non-ICU percentages were 35.5% versus 20.4% for imipenem-resistant Pseudomonas aeruginosa, 57.0% versus 47.0% for oxacillin-resistant Staphylococcus aureus, and 34.7% versus 17.2% for imipenem-resistant Klebsiella pneumoniae. Hospital-wide percentages were lower than the corresponding adult ICU percentages. Carbapenem-resistant A. baumannii and K. pneumoniae declined after false discovery rate correction, whereas methicillin-resistant S. aureus, carbapenem-resistant P. aeruginosa, and levofloxacin-resistant Escherichia coli showed no robust temporal trends. Excluding SARS-CoV-2 high-activity periods did not materially change the main findings. Care-setting-stratified cumulative antibiograms identified resistance heterogeneity not apparent from hospital-wide summaries and may complement hospital-wide reporting for local empirical therapy and stewardship guidance.
Indexed as
Identifiers
42538493What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.